Analysts Set Orchard Therapeutics PLC – (ORTX) Price Target at $23.40

Orchard Therapeutics PLC – (NASDAQ:ORTX) has earned a consensus recommendation of “Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $23.40.

A number of equities research analysts have issued reports on ORTX shares. Wedbush started coverage on Orchard Therapeutics in a research report on Sunday, December 2nd. They set an “outperform” rating and a $16.80 price objective on the stock. Goldman Sachs Group upgraded Orchard Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $18.00 to $21.00 in a research report on Monday, December 17th. ValuEngine downgraded Orchard Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Finally, Zacks Investment Research upgraded Orchard Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Wednesday.

Shares of ORTX stock opened at $17.88 on Wednesday. Orchard Therapeutics has a 1 year low of $8.65 and a 1 year high of $19.49. The company has a market cap of $1.46 billion and a price-to-earnings ratio of -1.75.

Hedge funds have recently modified their holdings of the business. Victory Capital Management Inc. purchased a new stake in Orchard Therapeutics during the fourth quarter valued at approximately $106,000. Northern Trust Corp bought a new position in shares of Orchard Therapeutics during the fourth quarter valued at approximately $579,000. Norges Bank bought a new position in shares of Orchard Therapeutics during the fourth quarter valued at approximately $629,000. Dean Capital Investments Management LLC bought a new position in shares of Orchard Therapeutics during the fourth quarter valued at approximately $674,000. Finally, Sofinnova Investments Inc. bought a new position in shares of Orchard Therapeutics during the fourth quarter valued at approximately $3,502,000. Institutional investors and hedge funds own 57.87% of the company’s stock.

About Orchard Therapeutics

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Featured Article: Why Invest in Dividend Achievers?

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.